Načítá se...
A Review on Cardiovascular Outcome Studies of Dipeptidyl Peptidase-4 Inhibitors
The U.S. Food and Drug Administration issued a guidance for pharmaceutical industry defining preapproval and postapproval requirements for the demonstration of cardiovascular (CV) safety for all new medications developed for glycemic management in type 2 diabetes. However, results published from the...
Uloženo v:
| Vydáno v: | Indian J Endocrinol Metab |
|---|---|
| Hlavní autoři: | , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Medknow Publications & Media Pvt Ltd
2018
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6166543/ https://ncbi.nlm.nih.gov/pubmed/30294582 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4103/ijem.IJEM_104_18 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|